ライフサイエンスコーパス: low-density lipoprotein cholesterol

1 icacy and safety of markedly lowering LDL-C (low-density lipoprotein cholesterol).

2 that includes potent statin therapy and low low-density lipoprotein cholesterol.

3 n, blood pressure, albuminuria, smoking, and low-density lipoprotein cholesterol.

4 ulating triglycerides and a 12% reduction in low-density lipoprotein cholesterol.

5 ent-specific ratios of triglycerides to very low-density lipoprotein cholesterol.

6 lycerols, apolipoproteins A-I and B, or very low-density lipoprotein cholesterol.

7 29) for triglycerides, and 95.0% (19/20) for low-density lipoprotein cholesterol.

8 ardiovascular risk as on-treatment levels of low-density lipoprotein cholesterol.

9 on trial in 45- to 64-year-old men with high low-density lipoprotein cholesterol.

10 ciated with lower adult weight and total and low-density lipoprotein cholesterol.

11 tergenic region near APOC1P1 associated with low-density lipoprotein cholesterol.

12 lycohemoglobin, systolic blood pressure, and low-density lipoprotein cholesterol.

13 e 1, 1.22; 95% CI, 1.01-1.48) independent of low-density lipoprotein cholesterol.

14 ished cardiovascular disease irrespective of low-density lipoprotein cholesterol.

15 betes mellitus, systolic blood pressure, and low-density lipoprotein cholesterol.

16 xcept for an inverse association of FT4 with low-density lipoprotein-cholesterol.

17 .45) but was not significantly different for low-density lipoprotein cholesterol (0.04 mg/dL; 95% CI,

18 tervention group had greater improvements in low-density lipoprotein cholesterol (-0.2 mmol/l; p < 0.

19 ipoprotein cholesterol (1.6 [1.2-2.2]), high low-density lipoprotein cholesterol (1.6 [1.1-2.1]), and

20 ]), obesity (3.7 [2.0-7.0]), borderline high low-density lipoprotein cholesterol (1.6 [1.2-2.2]), hig

21 rol, 184.74 mg/dL (178.17-191.31 mg/dL); for low-density lipoprotein cholesterol, 109.23 mg/dL (103.6

22 1% vs. 19% vs. 17%, respectively) and higher low-density lipoprotein cholesterol (117 vs. 107 vs. 103

23 idence interval, 18-27; P<1.0x10(-4)), lower low-density lipoprotein cholesterol (-12.2 mg/dL; 95% co

24 benefit based versus risk based) with higher low-density lipoprotein cholesterol (140 versus133 mg/dL

25 63.1%), LDL cholesterol (1.3 to 32.9%), very-low-density lipoprotein cholesterol (27.9 to 60.0%), non

26 patients after acute coronary syndrome with low-density lipoprotein cholesterol 50 to 125 mg/dL were

27 ed on 58 single-nucleotide polymorphisms for low-density lipoprotein cholesterol, 71 single-nucleotid

28 -8 mg/dl for total cholesterol, -8 mg/dl for low-density lipoprotein cholesterol, +8 mg/dl for remnan

29 nt of saturated with unsaturated fats lowers low-density lipoprotein cholesterol, a cause of atherosc

30 lipoprotein(a) is associated with increased low-density lipoprotein cholesterol, a family history of

31 e subtilisin/kexin type 9), markedly reduces low-density lipoprotein cholesterol across diverse patie

32 ype natriuretic peptide, and lower levels of low-density lipoprotein cholesterol, adiponectin, lipopr

33 The concentrations of low-density lipoprotein cholesterol and C-reactive prote

34 n/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular e

35 atory site for blood lipids, such as for the low-density lipoprotein cholesterol and coronary artery

36 me-wide significant variants associated with low-density lipoprotein cholesterol and coronary heart d

37 The interaction between low-density lipoprotein cholesterol and IHD genetic load

38 creased body mass index, active smoking, and low-density lipoprotein cholesterol and lipoprotein(a) l

39 nsistent relationship between lower achieved low-density lipoprotein cholesterol and lower risk of li

40 Lifelong genetic exposure to lower levels of low-density lipoprotein cholesterol and lower systolic b

41 Prevention Study) randomized men with raised low-density lipoprotein cholesterol and no history of my

42 s a promising new target for lowering plasma low-density lipoprotein cholesterol and preventing cardi

43 The confluence of low-density lipoprotein cholesterol and triglycerides ge

44 Reductions from baseline in LDL (low-density lipoprotein) cholesterol and Lp(a) (lipoprot

45 levation of aminotransferases, elevation of (low-density lipoprotein) cholesterol and steatosis in he

46 als has shown that therapies that lower LDL (low-density lipoprotein)-cholesterol and triglycerides r

47 ed candidate causal genes for schizophrenia, low-density-lipoprotein cholesterol and Crohn's disease.

48 The concentrations of high- and low-density-lipoprotein cholesterol and triglycerides ar

49 (A), biomarkers (B) (NT-proBNP, hs-cTnT, and low-density lipoprotein cholesterol), and clinical varia

50 with progressively higher levels of glucose, low-density lipoprotein cholesterol, and blood pressure.

51 ntrol subjects and had higher triglycerides, low-density lipoprotein cholesterol, and HbA1c and lower

52 LDL influence atherogenesis independently of low-density lipoprotein cholesterol, and high sensitivit

53 were adjusted for traditional risk factors, low-density lipoprotein cholesterol, and high-sensitivit

54 betes mellitus, high-density lipoprotein and low-density lipoprotein cholesterol, and IHD to create G

55 ted with higher blood HDL cholesterol, lower low-density lipoprotein cholesterol, and lower risk of c

56 High-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglyceride le

57 betes mellitus, systolic blood pressure, and low-density lipoprotein cholesterol appear to be the mos

58 s and cumulative exposure to lower levels of low-density lipoprotein cholesterol are not associated w

59 oach using only childhood lipid measures for low-density lipoprotein cholesterol (area under the rece

60 es more attention to percentage reduction in low-density lipoprotein cholesterol as a treatment goal

61 , decades of research has established LDL-C (low-density lipoprotein cholesterol) as a causal factor

62 The percent change in Lp(a) and low-density lipoprotein cholesterol at 48 weeks in patie

63 ine or aspartate aminotransferase, total and low-density lipoprotein cholesterol at baseline (<0.05),

64 re genome-wide significantly associated with low-density lipoprotein cholesterol based on 3203 subjec

65 atment to placebo in individuals with normal low-density lipoprotein cholesterol but increased C-reac

66 pe 9 (PCSK9) inhibitors substantially reduce low-density lipoprotein cholesterol, but it is presently

67 of all individuals to <130 mm Hg or lowering low-density lipoprotein cholesterol by 30% would be expe

68 Unregulated uptake of low-density lipoprotein cholesterol by circulating monoc

69 sult in lifelong exposure to lower levels of low-density lipoprotein cholesterol can provide informat

70 Pravastatin lowered low-density lipoprotein cholesterol (change in SD units

71 ificantly lower median time-weighted average low-density lipoprotein cholesterol compared with placeb

72 In secondary analyses conditioning on low-density lipoprotein cholesterol concentration, the e

73 and cardiovascular disease (CVD) context and low density lipoprotein-cholesterol concentrations withi

74 t-day humans, including variants involved in low-density lipoprotein cholesterol concentrations, schi

75 urrent average levels with elevated total or low-density lipoprotein cholesterol concentrations.

76 Pericardial fat volumes and LDL (low-density lipoprotein) cholesterol concentrations corr

77 nic profile scores for BMI, HDL cholesterol, low-density lipoprotein cholesterol, coronary artery dis

78 A and NPHSII, respectively; both p < 0.001), low-density lipoprotein cholesterol (correlation coeffic

79 -0.020 to -0.010] per year), mean levels of low-density lipoprotein cholesterol declined from 92 mg/

80 t showed differential responses in total and low-density lipoprotein cholesterol (decreased in LFHC g

81 s for neurocognitive impairment per 20 mg/dL low-density lipoprotein cholesterol decrements were 1.02

82 ng insulin, triglyceride, total cholesterol, low-density lipoprotein cholesterol, fasting glucose, di

83 olescents (aged 12-19 years), mean levels of low-density lipoprotein cholesterol, geometric mean leve

84 predictors of meeting trial goals for LDL-C (low-density lipoprotein cholesterol, goal <70 mg/dL) or

85 crucial areas: targeting of statin dose (not low-density lipoprotein cholesterol goals), additional t

86 burden related to phenotypic FH, defined by low-density lipoprotein cholesterol >/=190 mg/dL, is lik

87 h a third who had residual cholesterol risk (Low-density lipoprotein cholesterol >100 mg/dL).

88 Children with HeFH (age, 6-<18 years) and low-density lipoprotein cholesterol >4.9 mmol/L or >4.1

89 fying triglycerides >=135 and <500 mg/dL and low-density lipoprotein cholesterol >40 and <=100 mg/dL

90 500 mg/dl (median baseline of 216 mg/dl) and low-density lipoprotein cholesterol >40 and <=100 mg/dl

91 with triglycerides >150 but <=450 mg/dL and low-density lipoprotein cholesterol >=100 mg/dL (n=83 fo

92 s including diabetes mellitus, hypertension, low-density lipoprotein cholesterol >=100 mg/dl, and smo

93 es for secondary prevention in patients with low-density lipoprotein cholesterol >=70 mg/dL or non-hi

94 d with the highest versus lowest quartile of low-density lipoprotein cholesterol (>/= 146 versus </=

95 diabetes duration, systolic blood pressure, low-density lipoprotein cholesterol, hemoglobin A1c, alb

96 ated to cardiovascular disease risk factors: low-density lipoprotein cholesterol, high-density lipopr

97 Further adjustment for low-density lipoprotein cholesterol, high-density lipopr

98 signaling plays an essential role in LDL-C (low-density lipoprotein cholesterol) homeostasis through

99 ertensive medication use increased at higher low-density lipoprotein cholesterol in ARIC but not in R

100 hibitors were recently approved for lowering low-density lipoprotein cholesterol in heterozygous fami

101 s in the face of lower levels of circulating low-density lipoprotein cholesterol in mice lacking miR-

102 cholesterol, whereas EPA-only did not raise low-density lipoprotein cholesterol in very high triglyc

103 er of ER-derived cholesterol to the MVB when low-density lipoprotein-cholesterol in endosomes is low.

104 A1c was -0.022 +/- 0.53%; however, total and low-density lipoprotein cholesterol increased significan

105 high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), or total chol

106 ree potential risk factors for CAD including low density lipoprotein cholesterol (LDL-c), high densit

107 There was a significant reduction in low density lipoprotein-cholesterol (LDL-C), an increase

108 Plasma levels of total cholesterol (T-CHL), low density lipoprotein-cholesterol (LDL-CHL), and resis

109 For low-density lipoprotein cholesterol (LDL) of 130-159 mg/

110 Patients with primary elevations of low-density lipoprotein cholesterol (LDL-C) >/=190 mg/dL

111 with clinically evident atherosclerosis and low-density lipoprotein cholesterol (LDL-C) >=70 mg/dl o

112 se <126 mg/dl, total cholesterol <240 mg/dl, low-density lipoprotein cholesterol (LDL-C) <160 mg/dl,

113 us coronary intervention (PCI) with baseline low-density lipoprotein cholesterol (LDL-C) <=70 mg/dl a

114 -1.07]; P = .42) but resulted in higher mean low-density lipoprotein cholesterol (LDL-c) (2.86 vs 2.6

115 iglycerides (TGs), high-density (HDL-C), and low-density lipoprotein cholesterol (LDL-C) (n=627).

116 examine the rates of statin utilization and low-density lipoprotein cholesterol (LDL-C) achieved 1-y

117 rvational studies, and whether low levels of low-density lipoprotein cholesterol (LDL-C) alter this a

118 haracterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) and accelera

119 ma concentrations of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and apolipop

120 Despite widespread use of statins to reduce low-density lipoprotein cholesterol (LDL-C) and associat

121 -1 (GLP-1) secretion were increased, and the low-density lipoprotein cholesterol (LDL-C) and blood ur

122 e characterized by elevated plasma levels of low-density lipoprotein cholesterol (LDL-C) and extremel

123 Serum low-density lipoprotein cholesterol (LDL-C) and high-den

124 ic disorder, which causes elevated levels of low-density lipoprotein cholesterol (LDL-C) and increase

125 The relationship between exposure to lower low-density lipoprotein cholesterol (LDL-C) and lower sy

126 ontinuous relationship between reductions in low-density lipoprotein cholesterol (LDL-C) and major ad

127 Mean changes in fasting low-density lipoprotein cholesterol (LDL-C) and non-high

128 L-C remains a CVD risk factor when levels of low-density lipoprotein cholesterol (LDL-C) and triglyce

129 LDL) secretion, and subsequently circulating low-density lipoprotein cholesterol (LDL-C) and triglyce

130 Increased serum levels of low-density lipoprotein cholesterol (LDL-C) are an indep

131 Total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are heritabl

132 reased levels of total serum cholesterol and low-density lipoprotein cholesterol (LDL-C) at 6 months

133 dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 a

134 cumab + SOC persistently lowered mean +/- SE low-density lipoprotein cholesterol (LDL-C) by 56% +/- 0

135 to Target) showed the benefit of targeting a low-density lipoprotein cholesterol (LDL-C) concentratio

136 ular disease (CVD) increases with increasing low-density lipoprotein cholesterol (LDL-C) concentratio

137 opulations(3-5), despite having a lower mean low-density lipoprotein cholesterol (LDL-C) concentratio

138 oring nonfasting lipid assessment may affect low-density lipoprotein cholesterol (LDL-C) estimation.

139 cholesterolemia (FH) who are unable to reach low-density lipoprotein cholesterol (LDL-C) goals.

140 Low-density lipoprotein cholesterol (LDL-C) has been ass

141 elected individuals with increased levels of low-density lipoprotein cholesterol (LDL-C) have shown m

142 Elevated low-density lipoprotein cholesterol (LDL-C) is associate

143 Low-density lipoprotein cholesterol (LDL-C) is causally

144 Low-density lipoprotein cholesterol (LDL-C) is causally

145 um-tolerated statin therapy, with a baseline low-density lipoprotein cholesterol (LDL-C) level >=70 m

146 tients with elevated 10-year risk (>5%) or a low-density lipoprotein cholesterol (LDL-C) level of 4.9

147 y statins and targeting or using a threshold low-density lipoprotein cholesterol (LDL-C) level of les

148 s who do not achieve sufficient reduction in low-density lipoprotein cholesterol (LDL-C) level with a

149 LR), which in turn regulates the circulating low-density lipoprotein cholesterol (LDL-C) level.

150 h atherosclerotic cardiovascular disease and low-density lipoprotein cholesterol (LDL-C) levels >=70

151 cluding 511 adult patients with uncontrolled low-density lipoprotein cholesterol (LDL-C) levels and h

152 noclonal antibody against PCSK9 that reduces low-density lipoprotein cholesterol (LDL-C) levels by 55

153 itors in patients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels despi

154 ding of the harmful consequences of elevated low-density lipoprotein cholesterol (LDL-C) levels in yo

155 ter transfer protein (CETP) inhibitors lower low-density lipoprotein cholesterol (LDL-C) levels witho

156 type 9) inhibitors reduce lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C) levels.

157 scular events to the same extent as lowering low-density lipoprotein cholesterol (LDL-C) levels.

158 The primary outcome was the low-density lipoprotein cholesterol (LDL-C) levels.

159 Although controlling low-density lipoprotein cholesterol (LDL-C) may improve

160 amination of the effects of lifetime reduced low-density lipoprotein cholesterol (LDL-C) on cardiovas

161 10 mg/dl [0.26 mmol/l]; p < 0.001), but not low-density lipoprotein cholesterol (LDL-C) or HDL-C, we

162 adults even in the context of low levels of low-density lipoprotein cholesterol (LDL-C) or non-high-

163 However, the presence of an elevated low-density lipoprotein cholesterol (LDL-C) polygenic ri

164 In this study, higher baseline levels of low-density lipoprotein cholesterol (LDL-C) predicted gr

165 was shown that intraindividual variation in low-density lipoprotein cholesterol (LDL-C) predicts bot

166 Low-density lipoprotein cholesterol (LDL-C) reductions w

167 l benefit of nonstatin therapies that reduce low-density lipoprotein cholesterol (LDL-C) remains unce

168 atients with acute coronary syndromes (ACS), low-density lipoprotein cholesterol (LDL-C) target level

169 exin type 9 monoclonal antibodies can reduce low-density lipoprotein cholesterol (LDL-C) to very low

170 We sought to evaluate the achievement of low-density lipoprotein cholesterol (LDL-C) treatment go

171 Variants were weighted by associations with low-density lipoprotein cholesterol (LDL-C) using data f

172 Median untreated low-density lipoprotein cholesterol (LDL-C) was 239 mg/d

173 vestigated whether the relative reduction in low-density lipoprotein cholesterol (LDL-c) was a good i

174 density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measure

175 High-sensitivity CRP and low-density lipoprotein cholesterol (LDL-C) were measure

176 Importance: Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensi

177 igh-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyc

178 igh-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyc

179 igh-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyc

180 a monoclonal antibody that robustly reduces low-density lipoprotein cholesterol (LDL-C), for the tre

181 2 prior pregnancy losses; total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-densit

182 erized by elevated total cholesterol (TC) or low-density lipoprotein cholesterol (LDL-C), is associat

183 Elevated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), is frequent

184 ering of atherogenic lipoproteins, including low-density lipoprotein cholesterol (LDL-C), reduces the

185 effects are weaker on women than on men, for low-density lipoprotein cholesterol (LDL-C), uric acid (

186 Importance: Low-density lipoprotein cholesterol (LDL-C)-lowering all

187 orin Efficacy International Trial, intensive low-density lipoprotein cholesterol (LDL-C)-reducing the

188 key role in regulating the levels of plasma low-density lipoprotein cholesterol (LDL-C).

189 imarily expressed in the liver and regulates low-density lipoprotein cholesterol (LDL-C).

190 preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C).

191 could be useful for treating high levels of low-density lipoprotein cholesterol (LDL-C).

192 type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C).

193 iglycerides to a greater extent than they do low-density lipoprotein cholesterol (LDL-C): fibrates, n

194 the percent change (baseline to week 24) in low-density lipoprotein cholesterol (LDL-C); secondary e

195 The main outcomes included low-density lipoprotein cholesterol (LDL-cholesterol), h

196 igh polygenic load of a large number of LDL (low-density lipoprotein) cholesterol (LDL-C) or triglyce

197 2 have decreased ABCA1 expression, increased low-density lipoprotein-cholesterol (LDL-C) and choleste

198 igh-density-lipoprotein cholesterol (HDL-C), low-density-lipoprotein cholesterol (LDL-C), and/or trig

199 ring of remnant cholesterol (80% relative to low-density lipoprotein cholesterol [LDL-C]), but only m

200 rol, HDL-C, non-HDL-C, direct and calculated low-density lipoprotein cholesterol [LDL-C], and apolipo

201 igh-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], total chole

202 Low-density lipoprotein cholesterol(LDL-C) is a well est

203 the CC-genotype was associated with elevated low density lipoprotein cholesterol (LDLc) and total cho

204 with or without ezetimibe and reductions in low-density lipoprotein cholesterol (LDLc) and C-reactiv

205 ts of lipid profile [total cholesterol (TC), low-density lipoprotein cholesterol (LDLc), high-density

206 (women), triglyceride level <100 mg/dL, and low-density lipoprotein cholesterol level <100 mg/dL (n

207 l <6.2%, systolic blood pressure <120 mm Hg, low-density lipoprotein cholesterol level <2.0 mmol/L [<

208 CI, -0.82 to -0.16]; 23 trials [n = 58022]), low-density lipoprotein cholesterol level (-2.58 mg/dL [

209 gical cohorts, we stratified participants by low-density lipoprotein cholesterol level at index ages

210 rriers; 46% of statin-treated carriers had a low-density lipoprotein cholesterol level below 100 mg/d

211 , but approval rates did not vary by patient low-density lipoprotein cholesterol level nor statin use

212 that intensive lipid-lowering therapy (to a low-density lipoprotein cholesterol level of <70 mg/dl)

213 adults with a recent first MI and a baseline low-density lipoprotein cholesterol level of 1.81 mmol/L

214 eciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 m

215 The overall mean low-density lipoprotein cholesterol level was 26.5% lowe

216 The low-density lipoprotein cholesterol level was lower by a

217 Age, low-density lipoprotein cholesterol level, and pre-ART H

218 For the primary analysis, low-density lipoprotein cholesterol levels >/=190 and <1

219 d those with known ASCVD, diabetes mellitus, low-density lipoprotein cholesterol levels <70 or >/=190

220 ter publication) in the cohort with elevated low-density lipoprotein cholesterol levels (ie, >/=190 m

221 e subtilisin kexin type 9 inhibitors) reduce low-density lipoprotein cholesterol levels and cardiovas

222 , including reductions in blood pressure and low-density lipoprotein cholesterol levels and improveme

223 There was no relation between baseline low-density lipoprotein cholesterol levels and magnitude

224 ases in total, high-density lipoprotein, and low-density lipoprotein cholesterol levels compared with

225 atherosclerotic cardiovascular disease with low-density lipoprotein cholesterol levels of at least 7

226 counted net price of $10311 in patients with low-density lipoprotein cholesterol levels of at least 8

227 Individuals with elevated fasting low-density lipoprotein cholesterol levels were also ran

228 ter high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels were associat

229 Higher low-density lipoprotein cholesterol levels were not asso

230 sment of the efficacy and safety of lowering low-density lipoprotein cholesterol levels with atorvast

231 ns in continuous measures of blood pressure, low-density lipoprotein cholesterol levels, fasting gluc

232 Additional risk factors for CVD include low-density lipoprotein cholesterol levels, hypertension

233 iagnoses, lipid-lowering medication use, and low-density lipoprotein cholesterol levels.

234 been found to lower blood pressure (BP) and low-density lipoprotein cholesterol levels.

235 levels and increases in serum creatinine and low-density lipoprotein cholesterol levels.

236 ss index, comorbidities and their treatment, low-density lipoprotein cholesterol, liver biochemistrie

237 high-density lipoprotein cholesterol, lower low-density lipoprotein cholesterol, lower triglycerides

238 Extended follow-up of statin-based low-density lipoprotein cholesterol lowering trials impr

239 24% (95% CI, 8-37; P=0.004) despite similar low-density lipoprotein cholesterol lowering.

240 w points to the highlights of the history of low-density lipoprotein-cholesterol lowering, with the d

241 Exposures: Low-density lipoprotein cholesterol-lowering alleles in

242 Results: Low-density lipoprotein cholesterol-lowering genetic var

243 acebo, in addition to effective statin-based low-density lipoprotein cholesterol-lowering treatment.

244 or >/=50 mg/dL (women) and triglycerides and low-density lipoprotein cholesterol <100 mg/dL (n = 780)

245 0%), systolic blood pressure <140 mm Hg, and low-density lipoprotein cholesterol <2.5 mmol/L were ass

246 ntion parameters-aspirin use, lipid control (low-density lipoprotein cholesterol <70 mg/dL or statin

247 ncomitant therapies, including patients with low-density lipoprotein cholesterol <70 mg/dl.

248 18.17%; 95% CI -21.14%, -15.19%; p < 0.001), low-density lipoprotein cholesterol (MD -22.94%; 95% CI

249 confidence interval (CI): 0.2, 4.6), higher low-density lipoprotein cholesterol (MD = 1.3 mg/dL, 95%

250 Current smoking, low-density lipoprotein cholesterol, multivessel CAD, di

251 Low-density lipoprotein cholesterol, non-high-density li

252 e and after 1 year: systolic blood pressure, low-density lipoprotein cholesterol, nonsmoking, physica

253 on the potential long-term effects of lower low-density lipoprotein cholesterol on neurocognitive im

254 NR also did not elevate low density lipoprotein cholesterol or dysregulate 1-car

255 edicted birth weight was not associated with low density lipoprotein cholesterol or triglycerides, bu

256 one of the scavenger receptors for oxidized low-density lipoprotein cholesterol (ox-LDL), plays a cr

257 in PCSK9 were associated with 36 mg/dL lower low-density lipoprotein cholesterol (P=3x10(-21)).

258 In multivariable analysis, older age, higher low-density lipoprotein cholesterol, pack per year of sm

259 iated with a higher concentration of smaller low-density lipoprotein cholesterol particles.

260 l/L, LF = -0.31 +/- 0.10 mmol/L; P = 0.024), low-density lipoprotein cholesterol (PY = -0.35 +/- 0.10

261 of early initiation of statin treatment for low-density lipoprotein cholesterol reduction in childre

262 is-methylation quantitative trait loci for a low-density lipoprotein cholesterol-related differential

263 NA that regulates LDLR and may contribute to low-density lipoprotein cholesterol response to statin t

264 oprotein cholesterol (TRL-C) and small-dense low-density lipoprotein cholesterol (sdLDL-C) concentrat

265 nt weight reduction and improved small dense low-density lipoprotein-cholesterol (sdLDL-C) profiles,

266 isk for targets for systolic blood pressure, low-density lipoprotein cholesterol, smoking, physical a

267 ucose, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, systolic blood pres

268 eye examination, hemoglobin A1c testing, and low-density lipoprotein cholesterol testing), prescribin

269 eye examination, hemoglobin A1c testing, and low-density lipoprotein cholesterol testing), prescribin

270 lycohemoglobin, systolic blood pressure, and low-density lipoprotein cholesterol than contemporary gu

271 entrations of triglyceride and low- and very-low-density lipoprotein cholesterol than controls, sugge

272 sed on benefits estimated from reductions in low-density lipoprotein cholesterol that occurred in PCS

273 Low-fat diets tend to improve low-density lipoprotein cholesterol the most, while lowe

274 A, suggesting that therapeutic modulation of low-density lipoprotein cholesterol, the lipoprotein lip

275 Intensive low-density lipoprotein cholesterol therapy with ezetimi

276 ing family history, more stringent age-based low-density lipoprotein cholesterol thresholds, or alter

277 Recipient mice all had low levels of low-density lipoprotein cholesterol to promote plaque re

278 whelming evidence to support lowering LDL-c (low-density lipoprotein cholesterol) to reduce cardiovas

279 trations (high-density lipoprotein [HDL] and low-density lipoprotein-cholesterol, total cholesterol,

280 herosclerotic Cardiovascular Risk in Adults, low-density lipoprotein cholesterol treatment thresholds

281 Also, total cholesterol, low-density lipoprotein cholesterol, triacylglycerol, gl

282 has been directed to agents that reduce LDL (low-density lipoprotein) cholesterol, triglyceride, and

283 Application of SCOPA to two GWAS of high-and low-density lipoprotein cholesterol, triglycerides and b

284 1 microbe intervention in rats reduced serum low-density lipoprotein cholesterol, triglycerides and t

285 Higher levels of apolipoprotein B, very-low-density lipoprotein cholesterol, triglycerides, digl

286 ex, fasting plasma glucose, glycohemoglobin, low-density lipoprotein cholesterol, triglycerides, high

287 oncentrations (either low or high) of plasma low-density lipoprotein cholesterol, triglycerides, or h

288 index; waist circumference; total, high and low density lipoprotein cholesterol; triglycerides; gluc

289 res reviewed reduced total cholesterol, very low-density lipoprotein cholesterol (VLDL-C) and LDL-C.

290 Mean estimated untreated low-density lipoprotein cholesterol was 206 mg/dL in tho

291 per 1% glycohemoglobin difference), whereas low-density lipoprotein cholesterol was associated with

292 The median admission low-density lipoprotein cholesterol was lower among pati

293 High levels of low-density lipoprotein cholesterol were associated with

294 Reductions in mean levels of total and low-density lipoprotein cholesterol were greater after d

295 s coronary intervention, and higher level of low-density lipoprotein cholesterol were independent pre

296 , fasting plasma triglycerides and high- and low-density lipoprotein cholesterol were measured in 34

297 or triglyceride lowering and do not increase low-density lipoprotein cholesterol when used as monothe

298 ensitivity cardiac troponin T (hs-cTnT), and low-density lipoprotein cholesterol, where NT-proBNP and

299 erides by >=30% with concurrent increases in low-density lipoprotein cholesterol, whereas EPA-only di

300 Moreover, lowering of low-density lipoprotein cholesterol with evolocumab redu